The resumption of production at Baxter's facility is likely to have a positive short-term impact on the stock price as it alleviates concerns about supply disruptions and potential revenue loss. The facility's return to full operation suggests that Baxter can meet demand for its dialysis solutions, which is crucial for maintaining its market position.